Hypertrophic Cardiomyopathy (HCM)
Pathophysiology
➤Defined as unexplained ventricular hypertrophy (no due to systemic HTN or AS). Histopathologic features are myocardial fiber disarray, myocyte hypertrophy, and interstitial fibrosis.
➤ Cause is felt to be a genetic defect involving of the cardiac sarcomatic proteins (>100 mutations associated with development of autosomal dominant inheritance)
➤ Clinical manifestations
⤱ Asymptomatic
⤱ Dyspnea
⤱ Angina
⤱ Presyncope/syncope-LV outflow obstruction or arrythemia
⤱ CHF
⤱ Arrythemias
⤱ Sudden death (may be first manifestation)
Henodynamic Classification
➤ Hypertrophic obstructive cardiomyopathy (HOCM): dynamic outflow tract LVOT obstruction.
⤱ Either resting or provocable LVOT obstruction
➤ Non-obstructive hypertrophic cardiomyopathy decreased compliance and diastolic dysfunction (imparied filling)
➤ Complications; obstruction, arrythemia, diastolic dysfunction
Hallmark Signs of HOCM
➤Pulses
⤱ Rapid upstroke pulse
⤱ Bifid pulse
➤Precordial palpation
⤱ PMI: localized, sustained, double impulse, 'triple ripple' (triple apical impulse)
➤Precordial ascultation
⤱ Normal or paradoxically split S2
⤱ S4
⤱ Harsh, systolic, diamond shaped mumur at LISB or apex, enhanced by squat to standing or valsalva (mumur secondary to LVOT obstruction mitral regurgitation)
Investigations
➤ 12 lead ECG
⤱ LVH
⤱ Prominent Q waves septal or tall r wave in V1
➤ Echocardiography
⤱ LVH - asymmetric septal hypertrophy (most common presentation)
⤱ Systolic anterior motion (SAM) of anterior MV leaflet
⤱ Resting or dynamic ventricular outflow tract obstruction
⤱ MR (due to SAM and associated with LVOT obstruction)
⤱ Diastolic dysfunction
⤱ LAE
➤ Cardiac catheterization
⤱ Increased LV end-diastolic pressure
⤱ Variable systolic gradient across LV tract
Natural History
➤ Variable
➤ Potential complications: A fib, VT, CHF, sudden death
➤ Risk factors for sudden death
⤱ Most reliable
⤱ History of survival cardiac arrest/sustained VT
⤱ Family history of multiple sudden deaths
⤱ Other factors associated with increased risk of sudden cardiac death (SCD)
⤱ Syncope
⤱ VT on ambulatory monitoring
⤱ Marked ventricular hypertrophy
⤱ Prevention of sudden death in high risk patients
= amoidarone or implantable cardioverter defibrillator (ICD)
Management
➤ Avoid extremes of excertion
➤ Avoid factors which increase obstruction
➤ Infective endocarditis prophylaxis for patients with obstructive HCM
➤ Treatment of obstructive HCM
⤱ Medical agents
⤱ β blockers
⤱ Dysopyramide
⤱ CCB only used in patient with no resting/provocable obstruction
⤱ Patient with drug-refractory sypmptoms
⤱ Options
1- Surgical myectomy
2- Septal ethanol ablation
3- Dual chamber pacing
➤ Treatment of ventricular arrhythmias - AMIO or ICD
➤ Adult first degree relatives of patients with HCM be screened (physical exam, ECG, 2D-ECHO) serially every 5 years.
➤Defined as unexplained ventricular hypertrophy (no due to systemic HTN or AS). Histopathologic features are myocardial fiber disarray, myocyte hypertrophy, and interstitial fibrosis.
➤ Cause is felt to be a genetic defect involving of the cardiac sarcomatic proteins (>100 mutations associated with development of autosomal dominant inheritance)
➤ Clinical manifestations
⤱ Asymptomatic
⤱ Dyspnea
⤱ Angina
⤱ Presyncope/syncope-LV outflow obstruction or arrythemia
⤱ CHF
⤱ Arrythemias
⤱ Sudden death (may be first manifestation)
Henodynamic Classification
➤ Hypertrophic obstructive cardiomyopathy (HOCM): dynamic outflow tract LVOT obstruction.
⤱ Either resting or provocable LVOT obstruction
➤ Non-obstructive hypertrophic cardiomyopathy decreased compliance and diastolic dysfunction (imparied filling)
➤ Complications; obstruction, arrythemia, diastolic dysfunction
Hallmark Signs of HOCM
➤Pulses
⤱ Rapid upstroke pulse
⤱ Bifid pulse
➤Precordial palpation
⤱ PMI: localized, sustained, double impulse, 'triple ripple' (triple apical impulse)
➤Precordial ascultation
⤱ Normal or paradoxically split S2
⤱ S4
⤱ Harsh, systolic, diamond shaped mumur at LISB or apex, enhanced by squat to standing or valsalva (mumur secondary to LVOT obstruction mitral regurgitation)
Investigations
➤ 12 lead ECG
⤱ LVH
⤱ Prominent Q waves septal or tall r wave in V1
➤ Echocardiography
⤱ LVH - asymmetric septal hypertrophy (most common presentation)
⤱ Systolic anterior motion (SAM) of anterior MV leaflet
⤱ Resting or dynamic ventricular outflow tract obstruction
⤱ MR (due to SAM and associated with LVOT obstruction)
⤱ Diastolic dysfunction
⤱ LAE
➤ Cardiac catheterization
⤱ Increased LV end-diastolic pressure
⤱ Variable systolic gradient across LV tract
Natural History
➤ Variable
➤ Potential complications: A fib, VT, CHF, sudden death
➤ Risk factors for sudden death
⤱ Most reliable
⤱ History of survival cardiac arrest/sustained VT
⤱ Family history of multiple sudden deaths
⤱ Other factors associated with increased risk of sudden cardiac death (SCD)
⤱ Syncope
⤱ VT on ambulatory monitoring
⤱ Marked ventricular hypertrophy
⤱ Prevention of sudden death in high risk patients
= amoidarone or implantable cardioverter defibrillator (ICD)
Management
➤ Avoid extremes of excertion
➤ Avoid factors which increase obstruction
➤ Infective endocarditis prophylaxis for patients with obstructive HCM
➤ Treatment of obstructive HCM
⤱ Medical agents
⤱ β blockers
⤱ Dysopyramide
⤱ CCB only used in patient with no resting/provocable obstruction
⤱ Patient with drug-refractory sypmptoms
⤱ Options
1- Surgical myectomy
2- Septal ethanol ablation
3- Dual chamber pacing
➤ Treatment of ventricular arrhythmias - AMIO or ICD
➤ Adult first degree relatives of patients with HCM be screened (physical exam, ECG, 2D-ECHO) serially every 5 years.

Comments
Post a Comment